5 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital
In this article, we will take a look at some important pharma stock picks of Steven Boyd's Armistice Capital.
Posts Tagged ‘Deerfield Management’
Hedge Fund and Insider Trading News: Ray Dalio, David Tepper, Sanjay Shah, Deerfield Management, Coatue Management, Dicks Sporting Goods Inc (DKS), and More
Like most so-called Tiger Cubs, the tech-focused hedge fund Coatue has lost significant money this year.
Hedge Fund and Insider Trading News: Ray Dalio, Nelson Peltz, Weight Watchers International, Inc. (WTW), Xeris Pharmaceuticals Inc (XERS), Carolina Financial Corporation (CARO), and More
Hedge fund legend Ray Dalio, who runs Bridgewater Associates, is widely considered to be one of the most successful hedge fund managers in the world.
Hedge Fund and Insider Trading News: Eddie Lampert, Elliott Management, Limelight Networks, Inc. (LLNW), The New York Times Company (NYT), Spectrum Pharmaceuticals, Inc. (SPPI), and More
In wanting to sell Sears’ assets to his investment vehicle ESL, chief executive Eddie Lampert is tacitly admitting his tenure has been a failure.
Five Stocks To Buy According To Top Biotech-Focused Funds
Biotechnology is a very interesting industry to invest in, but also very complex.
13G Filing: James E. Flynn and Natera Inc. (NTRA)
Please follow Deerfield Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Deerfield Management or update its stock...
13D Filing: James E. Flynn and AveXis Inc (AVXS)
Please follow Deerfield Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Deerfield Management or update its stock...
13D Filing: James E. Flynn and Adeptus Health Inc. (ADPT)
You can access the original SEC filing by clicking here.
13G Filing: James E. Flynn and Mannkind Corp (MNKD)
You can access the original SEC filing by clicking here.
Hedge Fund News: Bill Ackman, Deerfield Management, Elliott Management
It's official: Hedge fund titan Bill Ackman is moving Pershing Square Capital to a new neighborhood.
Vanda Pharmaceuticals Inc. (VNDA) Stock: Deerfield Management Cashes In 2.56 Million Shares
According to a freshly-amended 13G filing with the Securities and Exchange Commission, James E.
Adeptus Health Inc. (ADPT): James E. Flynn’s Deerfield Management Monitoring Search for New CEO
James E. Flynn, manager of Deerfield Management, recently contacted Gregory W. Scott, a member of the Board of Adeptus Health Inc.
5 Stocks That Healthcare Fund Deerfield Management Was Buying in Q2
Founded by James E. Flynn in 2000, Deerfield Management has grown to become one of the premier healthcare-focused investment management companies today.
Portola Pharmaceuticals Inc (PTLA): This Hedge Fund is Loading Up Following Stock’s Weakness
It's been a disastrous year for Portola Pharmaceuticals Inc (NASDAQ:PTLA) thus far, as the company has shed over 60% of its value year-to-date.
13D Filing: James Flynn’s Deerfield Management Takes 9.99% Stake in Newly-Public AveXis, Inc. (AVXS)
AveXis Inc (NASDAQ:AVXS) is the subject of a new 13D filing issued by James Flynn's Deerfield Management, which reveals a 2.24 million-share position in the stock, which you...
Billionaire Singer Lifts Stake in Cabelas Inc. (CAB), Deerfield Bets on Beloranib, Plus Two Other Moves
Numerous closely-watched hedge fund vehicles are currently disclosing their equity positions as of the end of 2015, so individual investors can monitor what moves hedge fund managers...
Billionaires James Flynn, David Abrams, Among the Elite Investors Buying These 4 Stocks Last Week
Individual investors might find hedge fund investing quite expensive, considering the 2-and-2o fee structure most hedge funds employ.
A Look At Smart Money Three Latest Moves
In new filings with the U.S. Securities and Exchange Commission, Kelly Cardwell’s Central Square Management, James E.
Smart Money Is Seeing Upside For These Three Companies
According to a recent filing with the SEC, Christopher Sackelton and Adam Grey's Coliseum Capital has acquired some 2.74 million shares of Universal Technical Institute, Inc...
Tiger Global Cuts Stake in Autohome, While Deerfield Buys More Shares of This Pharmaceutical Company
Federal funds future contracts suggest a 79% probability that the Federal Reserve will raise interest rates at the December policy meeting, an event which is expected to halt...
Elite Hedge Funds Make Big Moves In These 3 Healthcare Stocks
A Schedule 13G is a public filing that must be submitted with the SEC by every hedge fund manager or other investor who acquires ownership of more than 5% in a publicly-traded...
Elite Hedge Funds Believe These Two Stocks Are Golden Opportunities
There are not many signals at the moment that suggest a continuation of the so-called “correction”, except for the potential letdown of the current earnings report season.
Three Healthcare Stocks Hedge Funds Are Snapping Up
Is it a good time to buy Alimera Sciences Inc (NASDAQ:ALIM)? James E.
Sequenom, Aclaris, and Xenoport Making Waves Among Elite Healthcare Investors
Three prominent healthcare-focused funds that we track at Insider Monkey submitted filings with the SEC today, disclosing new or bulked up positions in three different healthcare...
Hedge Funds’ Make Moves On Newly-Public Biotech And “Undervalued” Broker
The U.S equities markets have seriously pulled back lately, so hedge funds and other investors are stumbling upon a greater number of quality investing opportunities.
Two Stocks That Have Deerfield Management And Anchor Bolt Capital Excited
In a recent filing with the Securities and Exchange Commission (SEC), James E.
Deerfield Management Discloses 3.66% Stake In Newly Public Company Global Blood Therapeutics Inc. (GBT)
James E. Flynn’s Deerfield Management has filed a Schedule 13G disclosing a 3.66% ownership stake in the newly public company Global Blood Therapeutics Inc.
Deerfield Management Buys More And More Imprivata Inc. (IMPR) Shares
James E. Flynn’s Deerfield Management has filed a 13G with the U.S. Securities and Exchange Commission regarding its ownership of shares of Imprivata Inc. (NYSE:IMPR).
James Flynn’s Deerfield Management Ups Its Stake In Neos Therapeutics Inc. (NEOS)
James E. Flynn’s Deerfield Management disclosed that it has upped its position in Neos Therapeutics Inc.
Deerfield Management Discloses Stake In Recently Public Neos Therapeutics Inc (NEOS)
Constantly on the hunt for biotechnology stocks, James E. Flynn has identified another potential winner.
Deerfield Management Ups Passive Stake In Streamline Health Solutions Inc. (STRM) To 12.18%
Deerfield Management, led by James E. Flynn, has increased its stake in Streamline Health Solutions Inc. (NASDAQ:STRM). In a newly-amended 13G filing with the U.S.
Does James Flynn Think the Entry Point For Healthways, Inc. (HWAY) Has Arrived, And Should You Enter?
According to a recent filing with the Securities and Exchange Commission, James E. Flynn's Deerfield Management has acquired about 2.47 million shares of Healthways, Inc.
Ken Griffin And James Flynn Are Not Wasting Any Time Getting In On These New IPOs
Ken Griffin's (pictured) Citadel Investment Group has acquired about 1.09 million shares of 8Point3 Energy Partners LP (NASDAQ:CAFD).
Deerfield Management Bets Big On Company It Polished Ahead Of IPO, Nivalis Therapeutics Inc (NVLS)
Following the initial public offering of Nivalis Therapeutics Inc (NASDAQ:NVLS) today, James E.
Deerfield Management Trims Holding In Antares Pharma Inc (ATRS) Just Before Disastrous Setback
According to a recent filing with the Securities and Exchange Commission, James E.
Deerfield Management’s Top Health Stocks ~ Auspex Pharmaceuticals Inc (ASPX), Horizon Pharma PLC (HZNP), AbbVie Inc (ABBV)
James Flynn's Deerfield Management has filed its 13F with the SEC for the reporting period of March 31, with the investment manager disclosing a public equity portfolio valued...
Carbylan Therapeutics Inc (CBYL): Broadfin’s Latest Move and Market Smashing Q1 Returns Inside
To say Kevin Kotler’s Broadfin Capital had exceptional Q1 returns from its 11 long positions in companies valued at $1 billion or more would be a gross understatement.
Biotech Hedge Fund Deerfield Management’s Top Stock Picks
James E. Flynn's Deerfield Management is one of the funds that is focused on the healthcare sector, investing around 70% of its portfolio in healthcare stocks.
Tonix Pharmaceuticals Holding Corp., Manning & Napier Inc: Deerfield, Ariel Open Bullish New Positions
James E. Flynn’s Deerfield Management entered a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) this week. According to the 13G Form filed with the U.S.
Funds Reveal New Positions in Peabody Energy Corporation (BTU), BIND Therapeutics Inc (BIND)
Two of our tracked funds have recently revealed in filings with the SEC that they’ve taken large new passive positions in a couple of stocks.
Auspex Pharmaceuticals Inc (ASPX): Deerfield Management Increase its Stake Following the Latest Public Offering of Stock
James E. Flynn’s Deerfield Management recently increased its stake in Auspex Pharmaceuticals Inc (NASDAQ:ASPX) by 1.5 million shares at $56.5 per share.
Alcobra Ltd (ADHD): Broadfin Capital and Deerfield Initiate Passive Stakes Following Public Offering
Kevin Kotler's Broadfin Capital and James Flynn's Deerfield Management have both initiated passive stakes in Alcobra Ltd (NASDAQ:ADHD).
Vanda Pharmaceuticals Inc (VNDA): Deerfield Management Increases Exposure Following Positive Announcement
James Flynn’s Deerfield Management disclosed an increase in its stake in Vanda Pharmaceuticals Inc (NASDAQ:VNDA) on Friday.
Synergy Pharmaceuticals Inc (SGYP), Proteon Therapeutics Inc (PRTO): James E. Flynn and Peter Kolchinsky Think These Stocks Look Healthy
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Proteon Therapeutics Inc (NASDAQ:PRTO) are in the spotlight as James E.
BioScrip Inc (BIOS), Proteon Therapeutics Inc (PRTO): GAMCO Investors and Deerfield Management Are Bullish on These Companies
Mario Gabelli’s GAMCO Investors and James E.
